Lixte Expands LB-100 Clinical Trials, Partners with Liora Technologies to Boost Cancer Therapy
Lixte Biotechnology’s lead candidate LB-100 is advancing through expanded clinical trials and a strategic partnership with Liora Technologies to enhance chemotherapy, radiation and immunotherapy efficacy while reducing toxicity. The agreement covers combination studies and aims to accelerate development across multiple cancer indications.
1. Precision Oncology Strategy with LB-100
Lixte’s lead small-molecule candidate LB-100 inhibits a unique biological target to sensitize tumors to chemotherapy, radiation and immunotherapy. Preclinical data indicate the compound may enhance efficacy while lowering systemic toxicity compared with standard regimens.
2. Strategic Partnership with Liora Technologies
The newly announced collaboration with Liora Technologies grants access to proprietary drug-delivery platforms for LB-100, supporting combination studies that integrate targeted release mechanisms. Financial terms include milestone payments and shared rights for future indications.
3. Expanded Clinical Trials
Lixte has initiated additional Phase 1/2 studies of LB-100 in combination with checkpoint inhibitors across solid tumor indications. Trial protocols now include multiple dosing cohorts and biomarker analyses to optimize therapeutic windows and patient selection.